{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:33:20Z","timestamp":1790973200209,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:00:00Z","timestamp":1288915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:00:00Z","timestamp":1288915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/leu.2010.254","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T09:41:39Z","timestamp":1288950099000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["A phase-2 trial of low-dose pomalidomide in myelofibrosis"],"prefix":"10.1038","volume":"25","author":[{"given":"K H","family":"Begna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R F","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,5]]},"reference":[{"key":"BFleu2010254_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG . The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314\u2013322.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2010254_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.","journal-title":"N Engl J Med"},{"key":"BFleu2010254_CR3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.","journal-title":"N Engl J Med"},{"key":"BFleu2010254_CR4","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319\u20134323.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456\u20131465.","journal-title":"N Engl J Med"},{"key":"BFleu2010254_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2001.02918.x","volume":"114","author":"G Barosi","year":"2001","unstructured":"Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M . Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 78\u201383.","journal-title":"Br J Haematol"},{"key":"BFleu2010254_CR7","first-page":"1027","volume":"91","author":"JF Abgrall","year":"2006","unstructured":"Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006; 91: 1027\u20131032.","journal-title":"Haematologica"},{"key":"BFleu2010254_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","volume":"130","author":"S Ochonisky","year":"1994","unstructured":"Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J . Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66\u201369.","journal-title":"Arch Dermatol"},{"key":"BFleu2010254_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","volume":"117","author":"MA Elliott","year":"2002","unstructured":"Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117: 288\u2013296.","journal-title":"Br J Haematol"},{"key":"BFleu2010254_CR10","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534\u20132541.","journal-title":"Blood"},{"key":"BFleu2010254_CR11","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1080\/1042819021000040008","volume":"43","author":"G Barosi","year":"2002","unstructured":"Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002; 43: 2301\u20132307.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2010254_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","volume":"22","author":"M Marchetti","year":"2004","unstructured":"Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424\u2013431.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0889-8588(03)00080-7","volume":"17","author":"G Barosi","year":"2003","unstructured":"Barosi G . Myelofibrosis with myeloid metaplasia. Hematol Oncol Clin North Am 2003; 17: 1211\u20131226.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFleu2010254_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158\u20131164.","journal-title":"Blood"},{"key":"BFleu2010254_CR15","doi-asserted-by":"crossref","unstructured":"Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood 2010. (in press).","DOI":"10.1182\/blood-2010-05-287417"},{"key":"BFleu2010254_CR16","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F . et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760\u20134766.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR17","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA . Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21: 1827\u20131828.","journal-title":"Leukemia"},{"key":"BFleu2010254_CR18","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269\u20133276.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR et al. Phase1\/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129\u2013130.","journal-title":"Am J Hematol"},{"key":"BFleu2010254_CR20","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008\u20135014.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR21","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563\u20134569.","journal-title":"J Clin Oncol"},{"key":"BFleu2010254_CR22","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, NL H et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th edn. International Agency for research on Cancer (IARC): Lyon, France, 2008."},{"key":"BFleu2010254_CR23","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497\u20131503.","journal-title":"Blood"},{"key":"BFleu2010254_CR24","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u20131708.","journal-title":"Blood"},{"key":"BFleu2010254_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","volume":"115","author":"K Hussein","year":"2010","unstructured":"Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A . International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115: 496\u2013499.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010254","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:33:28Z","timestamp":1711931608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,5]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["BFleu2010254"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.254","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,5]]},"assertion":[{"value":"22 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}